BR112022013468A2 - Proteínas rspo1 e seu uso - Google Patents

Proteínas rspo1 e seu uso

Info

Publication number
BR112022013468A2
BR112022013468A2 BR112022013468A BR112022013468A BR112022013468A2 BR 112022013468 A2 BR112022013468 A2 BR 112022013468A2 BR 112022013468 A BR112022013468 A BR 112022013468A BR 112022013468 A BR112022013468 A BR 112022013468A BR 112022013468 A2 BR112022013468 A2 BR 112022013468A2
Authority
BR
Brazil
Prior art keywords
rspo1
diabetes
protein
beta cells
beta cell
Prior art date
Application number
BR112022013468A
Other languages
English (en)
Portuguese (pt)
Inventor
COLLOMBAT Patrick
SILVANO Serena
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Cote D'azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Cote D'azur filed Critical Inst Nat Sante Rech Med
Publication of BR112022013468A2 publication Critical patent/BR112022013468A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112022013468A 2020-01-10 2021-01-08 Proteínas rspo1 e seu uso BR112022013468A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305016 2020-01-10
PCT/EP2021/050289 WO2021140209A1 (en) 2020-01-10 2021-01-08 Rspo1 proteins and their use

Publications (1)

Publication Number Publication Date
BR112022013468A2 true BR112022013468A2 (pt) 2022-09-13

Family

ID=69185555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013468A BR112022013468A2 (pt) 2020-01-10 2021-01-08 Proteínas rspo1 e seu uso

Country Status (10)

Country Link
US (1) US20230241161A1 (https=)
EP (1) EP4087863A1 (https=)
JP (2) JP7767289B2 (https=)
KR (1) KR20220152202A (https=)
CN (1) CN114929731A (https=)
AU (1) AU2021205639A1 (https=)
BR (1) BR112022013468A2 (https=)
CA (1) CA3163861A1 (https=)
IL (1) IL294571A (https=)
WO (1) WO2021140209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813594A (zh) * 2023-01-19 2025-10-17 迪奥根克斯公司 R-spondin蛋白的重组变体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO2008046649A1 (en) 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
WO2016193497A1 (en) * 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
JP2021020900A (ja) 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤
IL310154A (en) * 2021-07-15 2024-03-01 Diogenx Recombinant variants of r-spondin proteins and their use

Also Published As

Publication number Publication date
KR20220152202A (ko) 2022-11-15
IL294571A (en) 2022-09-01
EP4087863A1 (en) 2022-11-16
AU2021205639A1 (en) 2022-07-14
US20230241161A1 (en) 2023-08-03
CA3163861A1 (en) 2021-07-15
WO2021140209A1 (en) 2021-07-15
JP2026021430A (ja) 2026-02-10
JP2023509189A (ja) 2023-03-07
CN114929731A (zh) 2022-08-19
JP7767289B2 (ja) 2025-11-11

Similar Documents

Publication Publication Date Title
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
Park et al. Hypopigmentation and subcutaneous fat, muscle atrophy after local corticosteroid injection
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
ES2723887T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
Ghasemi et al. Iatrogenic botulism after the therapeutic use of botulinum toxin-A: a case report and review of the literature
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
BR112015025072A2 (pt) novo derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inóico, método de preparação do mesmo e composição farmacêutica para prevenção e tratamento de doenças metabólicas incluindo o mesmo como ingrediente eficaz
Courseau et al. Efficacy of intra-articular botulinum toxin in osteoarticular joint pain: a meta-analysis of randomized controlled trials
Chang et al. The effectiveness of platelet-rich plasma and radial extracorporeal shock wave compared with platelet-rich plasma in the treatment of moderate carpal tunnel syndrome
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112022013468A2 (pt) Proteínas rspo1 e seu uso
EP1846022B1 (en) Methods for treating adhesive capsulitis
BR112022014119A2 (pt) Administração oral de peptídeos
Kersschot Intra-articular Glucose Injections for Orthoregeneration of Frozen Shoulder. A Clinical Case.
Chen et al. Icariin inhibits apoptosis in OGD-induced neurons by regulating M2 pyruvate kinase
US9241963B2 (en) Medicament for treating muscle and skeletal diseases
Pandey et al. Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds
Kikuchi et al. Effects of apremilast on pustulotic arthro‐osteitis in a real‐world setting: Report of five cases.
Iqbal et al. Modern technologies in management of diabetes
Sussman et al. A focused review of clinical and preclinical studies of cell-based therapies in stroke
Maria Villa et al. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report
Beraldo et al. Regenerative Therapies inTendinopathies and PartialRotator Cuff Tears